Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Michael Ulz, an analyst from Morgan Stanley, reiterated the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 study ...

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics (VKTX – Research ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p<0.0001).